<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01063543</url>
  </required_header>
  <id_info>
    <org_study_id>0601069</org_study_id>
    <nct_id>NCT01063543</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Fondaparinux in Patients With Major Orthopedic Surgery</brief_title>
  <acronym>POP-A-RIX</acronym>
  <official_title>Population Pharmacokinetics of Fondaparinux Administered at Prophylactic Doses After Major Orthopedic Surgery in Everyday Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fondaparinux is a synthetic antithrombotic agent with specific anti-factor Xa activity. A&#xD;
      population pharmacokinetic model of fondaparinux, based on data obtained in patients included&#xD;
      in phase II/III trials, has been described. However, the validity of this model in everyday&#xD;
      practice needed to be confirmed. This study was a multicenter, prospective cohort study in&#xD;
      consecutive orthopedic patients treated with 2.5 mg of fondaparinux. Anti-Xa activities were&#xD;
      recorded in 809 patients. Population parameters and inter-individual variability were&#xD;
      estimated using NONMEM VI software. A two-compartment model with first-order absorption best&#xD;
      described fondaparinux pharmacokinetics. Covariates partly explaining inter-individual&#xD;
      variability were body weight, age and creatinine clearance estimated by the simplified&#xD;
      Modification of Diet in Renal Disease formula. A body weight less than 50 kg and moderate&#xD;
      renal failure increased drug exposure. These results suggest that fondaparinux&#xD;
      pharmacokinetics need to be confirmed in patient populations not fully assessed in phase&#xD;
      II/III studies&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To determine an anti-Xa activity value which is predicted of a haemorrhage risk</measure>
    <time_frame>day 9</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">997</enrollment>
  <condition>Orthopedic Surgery</condition>
  <arm_group>
    <arm_group_label>patients with blood sample</arm_group_label>
    <description>Patients with major orthopedic surgery and prophylactic doses of fondaparinux who have 3 blood sample during their hospitalization to measure anti-Xa activity</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood sample for anti-Xaactivity measure&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients with major orthopedic surgery who need prophylactic doses of fondaprinux&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patient who need leg major orthopedic surgery&#xD;
&#xD;
          -  age &gt; 18 years&#xD;
&#xD;
          -  patient who need prophylactic doses of fondaparinux&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  contra-indication to fondaparinux&#xD;
&#xD;
          -  renal insufficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick MISMETTI, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU SAINT-ETIENNE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHARRET Françoise</name>
      <address>
        <city>Annonay</city>
        <zip>07100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PEGOIX Michel</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ROSENCHER Nadia</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PETIT Pierre-Yves</name>
      <address>
        <city>Pierre Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BARRE Jeanne</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MAITRE Anne-Marie</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BAYLOT Denis</name>
      <address>
        <city>Saint-etienne</city>
        <zip>42013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZUFFEREY Paul</name>
      <address>
        <city>Saint-etienne</city>
        <zip>42100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <study_first_submitted>February 4, 2010</study_first_submitted>
  <study_first_submitted_qc>February 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2010</study_first_posted>
  <last_update_submitted>February 4, 2010</last_update_submitted>
  <last_update_submitted_qc>February 4, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2010</last_update_posted>
  <responsible_party>
    <name_title>Pr Patrick MISMETTI</name_title>
    <organization>Centre Hospitalier Universitaire de Saint Etienne</organization>
  </responsible_party>
  <keyword>fondaparinux</keyword>
  <keyword>orthopedic surgery</keyword>
  <keyword>patients with major orthopedic surgery</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

